Hao-Xiang Zhang

Hao-Xiang Zhang

Auto-generated profile, based on publicly available information

Hao-Xiang Zhang

Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
HZHaoxiang Zhang
Haoxiang Zhang
JCJiaoshun Chen
Jiaoshun Chen
XHXiaoqing Hu
Xiaoqing Hu
JBJianwei Bai
Jianwei Bai
TYTao Yin
Tao Yin
Pancreatic ductal adenocarcinomas (PDAC) is one of the stiffest malignancies with strong solid stresses. Increasing stiffness could alter cellular behavior and trigger internal signaling pathways and is strongly associated with a poor prognosis in PDAC. So far, there has been no report on of an experimental model that can rapidly construct and stably maintain a stiffness gradient dimension in both vitro and in vivo. In this study, a gelatin methacryloyl (GelMA)‐based hydrogel was designed for in vitro and in vivo PDAC experiments. The GelMA‐based hydrogel has porous, adjustable mechanical properties and excellent in vitro and in vivo biocompatibility. The GelMA‐based in vitro 3D culture method can effectively form a gradient and stable extracellular matrix stiffness, affecting cell morphology, cytoskeleton remodeling, and malignant biological behaviors such as proliferation and metastasis. This model is suitable for in vivo studies with long‐term maintenance of matrix stiffness and no significant toxicity. High matrix stiffness can significantly promote PDAC progression and tumor immunosuppression. This novel adaptive extracellular matrix rigidity tumor model is an excellent candidate for further development as an in vitro and in vivo biomechanical study model of PDAC or other tumors with strong solid stresses.

22 November 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XHXiao-Xiao Huang
Xiao-Xiao Huang
CXCheng-Ke Xie
Cheng-Ke Xie
YMYi-Chao Mo
Yi-Chao Mo
WLWei Li
Wei Li
YWYong-Ding Wu
Yong-Ding Wu
SCShi Chen
Shi Chen
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.

30 June 2025 in Cancer Research
Verified
Journal Article
Closed access
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. PDAC is characterized by prominent necrotic foci within the tumor and a high propensity for distant liver metastasis, leading to a poor prognosis. In this study, using patient-derived organoid models, single-cell RNA sequencing, and multiplex immunofluorescence staining of samples from patients with PDAC, in vivo TGFβ1 conditional knockout mouse models, and 3D in vitro models, we discovered that the formation of intratumoral necrotic foci in pancreatic cancer is closely associated with liver metastatic events. This process was triggered by the deficiency of the long noncoding RNA TRAF3IP2-AS1 that induced necroptosis, which was accompanied by an immunosuppressive microenvironment. Mechanistically, TRAF3IP2-AS1 blocked necroptosis by reducing the mRNA stability of MLKL through competitively binding to IGF2BP2. Loss of TRAF3IP2-AS1 also promoted necroptosis by promoting RIPK3 phosphorylation via interference with the ubiquitination of the phosphatase PPM1B that dephosphorylates RIPK3. Additionally, TRAF3IP2-AS1 deficiency promoted the release of TGFβ1 from tumor cells, which induced an M2-like immunosuppressive phenotype and the release of more TGFβ1. The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer. Significance: TRAF3IP2-AS1 deficiency drives necroptosis in pancreatic cancer cells to engender a prometastatic immunosuppressive niche mediated by TGFβ1 production, providing mechanistic understanding of necroptosis and therapeutic strategies for treating liver metastasis.

2 September 2025
Verified
Other
Open access
PDF file
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Supplementary Fig. S7 TRAF3IP2-AS1 deficiency regulates PPM1B ubiquitination through TRAF3IP2

11 December 2020 in Research Square
Verified
Preprint
Open access
PDF file
HZHaoxiang Zhang
Haoxiang Zhang
CGChenggang Gao
Chenggang Gao
JCJiaoshun Chen
Jiaoshun Chen
SWShihong Wu
Shihong Wu
JBJianwei Bai
Jianwei Bai
TYTao Yin
Tao Yin
Background: The current guidelines of the American Joint Committee on Cancer (AJCC) for the staging of exocrine pancreatic tumors seem inapplicable to malignant pancreatic intraductal papillary mucinous neoplasms (IPMN). Therefore, we aimed to improve the accuracy of clinical staging and prognosis for malignant IPMN.Methods: We extracted data of 2001 patients with malignant IPMN from the Surveillance, Epidemiology, and End Results database between 2000 and 2016. Of these, 1401 patients were assigned to the primary cohort and 600 patients to the validation cohort.Results: In Kaplan-Meier analysis of the primary cohort, the current AJCC guidelines were unable to distinguish between certain tumor substages (IA and IB in the 7th, IB and IIA in the 8th). The modified system we regrouped based on the median overall survival and hazard ratios was superior in tumor stage classifications. Age > 70 years, tumors located in the body or tail, high-grade differentiated tumors, surgery, chemotherapy, and TNM stage were identified as independent predictive factors of overall survival. Compared to that of TNM-based systems, the concordance index of the clinical predictive nomogram significantly improved (0.819; 95% confidence interval, 0.805–0.833), with excellent area under the receiver operating characteristic curves (1-, 3-, and 5-year: 0.881, 0.889, and 0.879, respectively). The calibration curves also showed good agreement between prediction and actual observation. In the analysis of treatment modalities, surgery resulted in better survival for all resectable IPMN. Chemotherapy is the treatment of choice for locally advanced or distant metastases patients.Conclusion: Our modified staging system improves the distinction of tumor stages. The nomogram was a more accurate and clinically reliable tool in prognosis prediction of patients with IPMN.

2 September 2025
Verified
Other
Open access
PDF file
YWYong-Ding Wu
Yong-Ding Wu
XHXiao-Xiao Huang
Xiao-Xiao Huang
HZHao-Xiang Zhang
Hao-Xiang Zhang
YPyu pan
yu pan
CXCheng-Ke Xie
Cheng-Ke Xie
SCShi Chen
Shi Chen
Supplementary Table S3 Characteristics of the organoids from the External Cohort